What are the commercial brand names of JAK inhibitor medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

JAK阻害薬の商品名

現在承認されているJAK阻害薬の主な商品名は以下の通りです:

承認済みJAK阻害薬

関節リウマチ・自己免疫疾患用

  • トファシチニブ (Tofacitinib) - ゼルヤンツ (Xeljanz) 1, 2
  • バリシチニブ (Baricitinib) - オルミエント (Olumiant) 2, 3, 2
  • ウパダシチニブ (Upadacitinib) - リンヴォック (Rinvoq) 4, 3
  • フィルゴチニブ (Filgotinib) - ジセレカ (Jyseleca) - 欧州・日本で承認 1, 4, 1
  • ペフィシチニブ (Peficitinib) - スマイラフ (Smyraf) - 日本で承認 1, 2, 1

アトピー性皮膚炎用

  • アブロシチニブ (Abrocitinib) - サイバインコ (Cibinqo) 3
  • ウパダシチニブ (Upadacitinib) - リンヴォック (Rinvoq) 3
  • バリシチニブ (Baricitinib) - オルミエント (Olumiant) - 欧州で承認 3

骨髄線維症用

  • ルキソリチニブ (Ruxolitinib) 5
  • フェドラチニブ (Fedratinib) 5
  • パクリチニブ (Pacritinib) 5
  • モメロチニブ (Momelotinib) 5

TYK2選択的阻害薬

  • デウクラバシチニブ (Deucravacitinib) - ソティクツ (Sotyktu) - 乾癬用 6

外用薬

  • デルゴシチニブ (Delgocitinib) - コレクチム (Corectim) - 日本で承認、アトピー性皮膚炎用 7
  • ルキソリチニブクリーム (Ruxolitinib cream) - オプゼルラ (Opzelura) - アトピー性皮膚炎用 7

重要な注意点

地域による承認状況の違い: フィルゴチニブとペフィシチニブは米国では未承認ですが、欧州や日本では使用可能です 1。バリシチニブはアトピー性皮膚炎に対して欧州では承認されていますが、米国FDAでは未承認です 3。

適応症による使用制限: 米国FDAは、JAK阻害薬を一般的にTNF阻害薬による治療歴のある患者に推奨しており、特に心血管リスク因子を持つ患者では慎重な使用が求められています 4。

References

7
Research

JAK inhibitors in the treatment of atopic dermatitis.

The Journal of allergy and clinical immunology, 2021

Related Questions

What are the different Janus kinase (JAK) inhibitors, their clinical indications, and associated adverse effects?
What are the indications, dosing, contraindications, and monitoring recommendations for momelotinib (oral Janus kinase‑1/2 inhibitor) in adults with myelofibrosis?
For a JAK‑inhibitor‑naïve myelofibrosis patient with moderate thrombocytopenia, which first‑line clinical trial is preferred, XPORT‑MF‑044 (selinexor) or KRT‑232‑115?
In a patient with autoimmune hepatitis on mycophenolate mofetil, can a Janus kinase (JAK) inhibitor be used to control his ulcerative colitis?
What laboratory tests are required before initiating Janus kinase (JAK) inhibitor therapy in Asian patients?
In a 48-year-old male with irregular antihypertensive medication use, normal oxygen saturation, normal heart rate, normal blood pressure, normal random glucose, and hypertriglyceridemia presenting with episodic chest heaviness, choking sensation, and bilateral hand and foot numbness, which investigations are recommended to rule out other causes of panic attacks and how should a severe panic episode be treated?
What percentage of patients on clopidogrel experience a clinically significant interaction when co‑administered with omeprazole?
According to the product information, can a patient be switched to sotalol if the QTc interval after amiodarone is less than 450 ms?
For a patient with symptomatic palpitations and preserved ejection fraction, which β‑blocker is preferred: propranolol or bisoprolol?
What are the trade names of the biologic agents used to treat rheumatoid arthritis?
What are the current guidelines for prescribing a proton‑pump inhibitor in a patient taking clopidogrel, including bleeding risk factors and preferred PPI choice?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.